CHILDREN'S NASACORT ALLERGY 24HR OTC
Generic Name and Formulations:
Triamcinolone acetonide 55mcg; per nasal spray; scent- and alcohol-free.
Indications for CHILDREN'S NASACORT ALLERGY 24HR:
Seasonal and perennial allergic rhinitis, including nasal congestion.
2 sprays in each nostril once daily. Reduce dose as symptoms improve.
<2yrs: not recommended. 2–<6yrs: 1 spray in each nostril once daily. 6–12yrs: 1 spray in each nostril once daily; max 2 sprays in each nostril once daily. Reduce dose as symptoms improve.
Avoid use in patients with recent nasal ulcers, surgery, or injury that has not healed. Infections (eg, ocular herpes simplex). Glaucoma. Cataracts. Discontinue if exposed to measles, chickenpox, or tuberculosis. Monitor for growth suppression in children. Avoid eyes or mucous membranes. Reevaluate if no improvement after 1 week. Pregnancy. Nursing mothers.
Avoid concomitant other steroid-containing products.
Infection, fever, visual changes, severe or frequent nosebleeds.
Nasal Spray—8.25g (60 sprays), 16.5g (120 sprays); Children's—8.25g (60 sprays)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML